Pubmed logo

Select publications

  1. Lue LF, Schmitz CT, Snyder NL, Chen K, Walker DG, Davis KJ, Belden C, Caviness JN, Driver-Dunckley E, Adler CH, Sabbagh MN, Shill HA. Converging mediators from immune and trophic pathways to identify Parkinson disease dementia. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(1):e193. doi: 10.1212/NXI.0000000000000193. eCollection 2016 Feb.

  2. Walker DG, Lue LF, Serrano G, Adler CH, Caviness JN, Sue LI, Beach TG. Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases. Front Neurosci. 2016 Jan 14;9:507. doi: 10.3389/fnins.2015.00507. eCollection 2015.


  1. Beach TG, Adler CH, Sue LI, Serrano G, Shill HA, Walker DG, Lue L, Roher AE, Dugger BN, Maarouf C, Birdsill AC, Intorcia A, Saxon-Labelle M, Pullen J, Scroggins A, Filon J, Scott S, Hoffman B, Garcia A, Caviness JN, Hentz JG, Driver-Dunckley E, Jacobson SA, Davis KJ, Belden CM, Long KE, Malek-Ahmadi M, Powell JJ, Gale LD, Nicholson LR, Caselli RJ, Woodruff BK, Rapscak SZ, Ahern GL, Shi J, Burke AD, Reiman EM, Sabbagh MN. Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.  Neuropathology. 2015 Aug;35(4):354-89. doi: 10.1111/neup.12189. Epub 2015 Jan 26.

  2. Yao XQ, Jiao SS, Saadipour K, Zeng F, Wang QH, Zhu C, Shen LL, Zeng GH, Liang CR, Wang J, Liu YH, Hou HY, Xu X, Su YP, Fan XT, Xiao HL, Lue LF, Zeng YQ, Giunta B, Zhong JH, Walker DG, Zhou HD, Tan J, Zhou XF, Wang YJ.  p75NTR ectodomain is a physiological neuroprotective molecule against amyloid-beta toxicity in the brain of Alzheimer's disease.  Mol Psychiatry. 2015 Nov;20(11):1301-10. doi: 10.1038/mp.2015.49. Epub 2015 Apr 28.

  3. Walker DG, Lue LF. Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains.  Alzheimers Res Ther. 2015 Aug 19;7(1):56. doi: 10.1186/s13195-015-0139-9.

  4. Lue LF, Schmitz C, Walker DG.  What happens to microglial TREM2 in Alzheimer's disease: Immunoregulatory turned into immunopathogenic?  Neuroscience. 2015 Aug 27;302:138-50. doi: 10.1016/j.neuroscience.2014.09.050. Epub 2014 Oct 2. Review.


  1. Lue LF, Schmitz CT, Serrano G, Sue LI, Beach TG, Walker DG 20 TREM2 Protein Expression Changes Correlate with Alzheimer's Disease Neurodegenerative Pathologies in Post-Mortem Temporal Cortices.  Brain Pathol. 2014 Sep 3. doi: 10.1111/bpa.12190.

  2. Walker DG, Whetzel AM, Serrano G, Sue LI, Beach TG, Lue LF. Association of CD33 polymorphism rs3865444 with Alzheimer's disease pathology and CD33 expression in human cerebral cortex. Neurobiol Aging. 2014 Oct 2. pii: S0197-4580(14)00629-0. doi: 10.1016/j.neurobiolaging.

  3. Walker DG, Whetzel AM, Lue LF. Expression of suppressor of cytokine signaling genes in human elderly and Alzheimer's disease brains and human microglia. Neuroscience. 2014 Oct 5. pii: S0306-4522(14)00803-3. doi: 10.1016/j.neuroscience.2014.09.052.


Walker DG and Lue LF.  Understanding the neurobiology of CD200 and the CD200 receptor: a therapeutic target for controlling inflammation in human brains? Future Neurol. 2013 May;8(3). doi: 10.2217/fnl.13.14.


  1. Walker DG, Lue LF, Adler CH, Shill HA, Caviness JN, Sabbagh MN, Akiyama H, Serrano GE, Sue LI, Beach TG (2012) Changes in properties of serine 129 phosphorylated alpha-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol 240C:190-204. doi: 10.1016/j.expneurol.2012.11.020.:190-204.

  2. Lue LF, Andrade C, Sabbagh M, Walker D. Is There Inflammatory Synergy in Type II Diabetes Mellitus and Alzheimer's Disease? Int J Alzheimers Dis 2012:918680. doi: 10.1155/2012/918680. Epub; 2012 Jun 21.:918680.

  3. Castano EM, Maarouf CL, Wu T, Leal MC, Whiteside CM, Lue LF, Kokjohn TA, Sabbagh MN, Beach TG, Roher AE.  Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations. 2012, Neurochem Int 62:145-156.

  4. Lue LF, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, Sue LI, Caviness J, Sabbagh MN, Beach TG. Biochemical Increase in Phosphorylated Alpha-Synuclein Precedes Histopathology of Lewy-Type Synucleinopathies. Brain Pathol. 2012 Feb 27.

  5. Fang F, Chen X, Huang T, Lue LF, Luddy JS, Yan SS. Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model. Biochim Biophys Acta. 2012 Feb; 1822(2):286-92.

  6. Shill HA, Adler CH, Beach TG, Lue L, Caviness JN, Sabbagh MN, Sue LI and Walker DG. Brain biochemistry in autopsied patients with essential tremor. 2012 Jan: 27(1):113.


  1. Caviness JN, Lue LF, Beach TG, Hentz JG, Adler CH, Sue L, Sadeghi R, Driver-Dunckley E, Evidente VG, Sabbagh MN, Shill HA, Walker DG. Parkinson's disease, cortical dysfunction, and alpha-synuclein. Mov Disord. 2011 Jul;26(8):1436-42.

  2. Arab L, Sadeghi R, Walker DG, Lue LF, Sabbagh MN. Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer's Disease. Curr Neuropharmacol. 2011 Dec;9(4):693-705.

  3. Yao J, Du H, Yan S, Fang F, Wang C, Lue LF, Guo L, Chen D, Stern DM, Gunn Moore FJ, Xi Chen J, Arancio O, Yan SS.  Inhibition of Amyloid-{beta} (A{beta}) Peptide-Binding Alcohol Dehydrogenase-Aß Interaction Reduces Aß Accumulation and Improves Mitochondrial Function in a Mouse Model of Alzheimer's Disease. J Neurosci. 2011 Feb 9;31(6):2313-20.

  4. Caviness JN, Lue L, Adler CH, Walker DG. Parkinson's disease dementia and potential therapeutic strategies. CNS Neurosci Ther. 2011 Feb;17(1):32-44.

  5. Beach TG, Maarouf CL, Brooks RG, Shirohi S, Daugs ID, Sue LI, Sabbagh MN,Walker DG, Lue L, Roher AE. Reduced clinical and postmortem measures of cardiacpathology in subjects with advanced Alzheimer's Disease. BMC Geriatr. 2011 Jan, 25;11(1):3.

  6. Ryan L, Walther K, Bendlin BB, Lue LF, Walker DG, Glisky EL. Age-related differences in white matter integrity and cognitive function are related to APOE status. Neuroimage. 2011 Jan 15;54(2):1565-77.


  1. Birdsill AC, Walker DG, Lue L, Sue LI, Beach TG. Postmortem interval effect on RNA and gene expression in human brain tissue. Cell Tissue Bank. 2010 Aug 12.

  2. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG; Arizona Parkinson's Disease Consortium. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010 Jun;119(6):689-702. Epub 2010 Mar 21.

  3. Lue LF, Kuo YM, Beach T, Walker DG. Microglia activation and anti-inflammatory regulation in Alzheimer's disease. Mol Neurobiol. 2010 Jun;41(2-3):115-28. Epub 2010 Mar 3. Review. PubMed PMID: 20195797.


  1. RAGE-dependent signaling in microglia contributes to neuroinflammation, Aßaccumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. Fang F, Lue LF, Yan S, Xu H, Luddy JS, Chen D, Walker DG, Stern DM, Yan S, Schmidt AM, Chen JX, Yan SS. FASEB J. 2009 Nov 11. [Epub ahead of print]

  2. Vukic V, Callaghan D, Walker DG, Lue LF, Liu QY, Couraud PO, Romero IA, Weksler B, Stanimirovic DB, Zhang W.  Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway.  Neurobiol Dis. 2009 34(1):95-106.

  3. Xiong H, Callaghan D, Jones A, Bai J, Rasquinha I, Smith C, Pei K, Walker DG, Lue LF, Stanimirovic D, Zhang W.  ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta (1-40) peptides.  J Neurosci. 2009 29(17):5463-75.

  4. Lue, L.F., Walker, D.G., Jacobson, S., Sabbagh, M.N. Receptor for advanced glycation end products: its role in Alzheimer’s disease and other neurological diseases.  Future Neurology 2009, 4; 167-177.

  5. Beach TG, Adler CH, Lue LF, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL 3rd, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG.  Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 2009. 117(6):613-34.

  6. Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF.  Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation.  Exp Neurol. 2009 Jan;215(1):5-19. Epub 2008 Sep 24.


  1. Van Vickle GD, Esh CL, Daugs ID, Kokjohn TA, Kalback WM, Patton RL, Luehrs DC, Walker DG, Lue LF, Beach TG, Davis J, Van Nostrand WE, Castano EM, Roher AE. Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy. Am J Pathol. 2008 Aug;173(2):483-93. Epub 2008 Jul 3.

  2. Sabbagh MN, Walker DG, Reid RT, Stadnick T, Anand K, Lue LF. Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw, Ind). Neurosci Lett. 2008 Dec 26;448(2):217-20.Epub 2008 Oct 7.

  3. Beach TG, Sue LI, Walker DG, Roher AE, Lue LF, Vedders L, Connor DJ, Sabbagh MN, Rogers J. The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank. 2008 Sep;9(3):229-45. Epub 2008 Mar 18.

  4. Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J,  Dalsing-Hernandez JE, Lue LF, Caviness JN, Connor DJ, Sabbagh MN, Walker DG.  Reduced striatal tyrosine hydroxylase in incidental Lewy body disease.  Acta Neuropathol. 2008 Apr;115(4):445-51. Epub 2007 Nov 6.

  5. Xiong H, Callaghan D, Jones A, Walker DG, Lue LF, Beach TG, Sue LI, Woulfe J, Xu H, Stanimirovic DB, Zhang W.  Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis. 2008 Mar;29(3):422-37. Epub 2007 Nov 4.


  1. Walker D.G., Lue, L-F.  Anti-inflammatory and immune therapy for Alzheimer's disease: Current status and future directions.  Current Neuropharmacol. 2007, 5; 232-243.

  2. Walker DG, Dalsing-Hernandez JE, Lue LF. Human postmortem brain-derived cerebrovascular smooth muscle cells express all genes of the classical complement pathway: A potential mechanism for vascular damage in cerebral amyloid angiopathy and Alzheimer's disease.  Microvasc Res. 2008 Apr;75(3):411-9..

  3. Beach TG, Sue LI, Walker DG, Lue LF, Connor DJ, Caviness JN, Sabbagh MN, Adler CH.Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits.Acta Neuropathol. 2007,114:419-24.

  4. Chen X., Walker DG, Schmidt AM, Arancio O, Lue L-F, Yan SD. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer’s disease.  Curr Mol Med. 7:735- 42, 2007.

  5. Beach T, Sue L, Walker DG, Lue L-F, Connor DJ, Caviness JN, Sabbagh MN, Adler CH. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol, 114:419-424, 2007.


  1. Moses GSD, Jensen MD, Lue L-F, Walker DG, Sun AY, Simonyi A, and Sun GY. Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease.  J. Neuroinflam, 3:28, 2006.

  2. Walker G, Link J, Lue LF, Dalsing-Hernandez JE, Boyes BE.  Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes.  J. Leukocy. Biol., 79:596-610, 2006.


  1. Wu J, Xu L, Kim DY, Rho JM, St. John PA, Lue LF, Coon S, Ellsworth K, Nowak L, Johnson E, Rekate H, Kerrigan JF. Eletrophysiological properties of human hypothalamic hemartomas. Ann Neurol, 58:371-382, 2005.

  2. Walker DG, Lue L-F.  Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer’s disease and other neurodegenerative diseases.  J. Neurosci Res, 81:412-425, 2005.

  3. Lue L-F, Yan SD, Stern D, Walker DG.  Preventing activation of receptor for advanced glycation endproducts in Alzherimer’s disease.  Current Drug Targets-CNS & Neurological Disorders, 4:249-266, 2005.

  4. McLarnon JG, Choi HB, Lue L-F, Walker DG, Kim SU.  Perturbations in calcium-mediated signal trasnduction in microglia from Alzheimer’s disease patients.  J Neurosci Res, 81:426-435. 2005.

  5. Townsend KP, Town T, Mori T , Lue L-F, Shytle D,  Sanberg  PR, Morgan D, Fernandez F , Flavell RA, Tan J.  CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid ß peptide.  Eur. J. Immunol., 35:901-910, 2005.


  1. Morelli L, Llovera RE, Mathov I, Lue L-F, Frangione B, Ghiso J, Castano E. Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid ß vasculotropic variants and reduced activity in cerebral amyloid angiopathy.  J. Biol Chem., 279:56004-56013, 2004.

  2. Lustbader JW, Cirill M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue L-F Walker DG, Kuppusamy P, Zewier ZL,  Arancio O, Stern D, Yan S, Wu H.  ABAD Directly Links Aß to Mitochondrial Toxicity in Alzheimer’s Disease. Science, 304:448-452, 2004.

  3. Ottavio A, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, Liu S, Hegde A, Yan SF, Stern A, Luddy JS, Lue L-F, Walker DG, Roher A, Buttini M, Mucke L, Li W, Schmidt AM, Kindy M, Hyslop PA, Stern DM, Yan SSD. RAGE potentiates Aß-induced perturbation of neuronal function in transgenic mice. The EMBO Journal, 23: 4096-4105, 2004.

  4. Li R, Strohmeyer R, Zhe L, Lue L-F, Rogers J.  CCAAT/enhancer binding protein  (C/EBP) expression and elevation in Alzheimer’s disease.  Neurobiol. Aging, 25:991-999, 2004.


  1. Lue L-F and Walker DG. Modeling Alzheimer’s disease immune therapy mechanisms: Interactions of human microglia with antibody-opsonized amyloid beta peptide, J. Neurosc Res, 70:599-610, 2002.

  2. Walker DG. Lue L-F, Beach TG. Increased expression of the urokinase plasminogen-activator receptor in amyloid beta peptide-treated human brain microglia and in AD brains. Brain Res, 926:69-79, 2002.


  1. Walker DG, Lue L-F, Beach TG. Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. Neurobiology of Aging, 22:957-966, 2001.

  2. Lue L-F, Walker DG,  Rogers J. Modeling microglial activation in Alzheimer’s disease using human postmortem microglial cultures. Neurobiol of Aging, 22:945-956, 2001.

  3. Lue L-F, Rydel R, Brigham EF; Yang LB, Hampel H, Murphy GM Jr, Brachova L, Yan SD, Walker D G, Shen Y, and Rogers J. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia. 35:72-9, 2001.

  4. Rogers J and Lue L-F. Microglial chemotaxis, activation, and phagocytosis of amyloid beta peptide as linked phenomenon in Alzheimer’s disease.  Neurochem Int. 39:333-40, 2001.

  5. Lue L-F, Walker D G, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD. Involvement of Microglial Receptor for Advanced Glycation Endproducts (RAGE) in Alzheimer’s Disease: Identification of a Cellular Activation Mechanism. Exp. Neurol. 171: 29-45, 2001.


Li R, Shen Y, Yang L-B, Lue L-F, Finch C, Rogers J. Estrogen enhances uptake of amyloid beta-protein by microglia derived from the human cortex. J Neurochem. 75(4):1447-54, 2000.

Before 1999

  1. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE and Rogers J.  Soluble amyloid ß peptide concentration as a predictor of synaptic change in Alzheimer’s disease.  Am. J. Pathol. 155:853-862, 1999.

  2. Lue LF, Brachova L, Walker DG, Rogers J. Characterization of glial cultures from rapid autopsies of Alzheimer's and control patients. Neurobiol Aging. 1996, 17(3):421-9.

  3. Brachova L, Lue LF, Schultz J, el Rashidy T, Rogers J. Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease. Brain Res Mol Brain Res. 1993;18(4):329-34.

  4. Rogers J, Schultz J, Brachova L, Lue LF, Webster S, Bradt B, Cooper NR, Moss DE Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease. Res Immunol. 1992;143(6):624-30.

  5. Dellmann HD, Lue LF, Bellin SI, Quassat M. Magnocellular neurosecretory axon regeneration into rat intrahypothalamic optic nerve allografts. J Neurosci Res. 1989 Oct;24(2):163-8.

  6. Dellmann HD, Lue LF, Bellin SI, Ouassat M. An immunohistochemical and fine-structural analysis of peptidergic hypothalamic neurosecretory axon regeneration into the leptomeninges of the rat. Brain Res. 1988 May 31;450(1-2):181-9.

  7. Dellmann HD, Lue LF, Bellin SI. Neurosecretory axon regeneration into intrahypothalamic neural lobe allografts: neurophysin immunohistochemistry and fine structure.  Exp Brain Res. 1987;67(3):543-55.

  8. Dellmann HD, Lue LF, Bellin SI. Fine structural characteristics of neurophysin-positive perivascular plexus that develop in the rat hypothalamus following interruption of the hypothalamo-neurohypophysial tract. Cell Tissue Res. 1987 Jan;247(1):137-43.